Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
NCT04524871 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Tocilizumab
- DRUG Bevacizumab 15 mg/kg
- DRUG Tiragolumab
- DRUG TPST-1120
Study Locations (20)
California
- UC Irvine Medical Center — Costa Mesa
- City of Hope — Duarte
- UC Irvine Medical Center — Orange
- University of California San Diego Medical Center — San Diego
- University of California San Francisco Cancer Center — San Francisco
- UCLA Center for East — Santa Monica
Other
- Beijing Cancer Hospital — Beijing
- Zhongshan Hospital Fudan University — Shanghai
- Centre Georges Francois Leclerc — Dijon
- CHU Hôpitaux de Marseille — Marseille
Colorado
- Cherry Creek Medical Center — Aurora
- University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora
- UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital — Highlands Ranch
Texas
- Parkland Health & Hospital System — Dallas
- The University of Texas Southwestern Medical Center at Dallas — Dallas
Connecticut
- Smilow Cancer Hospital at Yale New Haven — New Haven
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Kentucky
- University of Kentucky - Markey Cancer Center — Lexington
Oregon
- Oregon Health & Science University — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524871
The ClinicalTrials.gov registry entry for NCT04524871 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Advanced Liver Cancers appearing as the primary indexed condition, and to 5 interventions — of which Atezolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04524871 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Other, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04524871 about?
NCT04524871 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)". This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or...
What is the current status of trial NCT04524871?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 518 participants. The study started on 2020-11-01. Estimated completion is 2027-12-31.
What conditions does trial NCT04524871 study?
This clinical trial studies the following conditions: Advanced Liver Cancers. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04524871?
The interventions under investigation include: Atezolizumab (DRUG), Tocilizumab (DRUG), Bevacizumab 15 mg/kg (DRUG), Tiragolumab (DRUG), TPST-1120 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04524871?
This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04524871 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.